Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
ViaCyte wins $6M to advance stem cell treatment for diabetes
The California Institute for Regenerative Medicine and JDRF, the type 1 diabetes research advocacy group, have agreed to give $3 million each to support ViaCyte's development of a stem cell treatment for type 1 diabetes. ViaCyte plans a regulatory application to conduct proof-of-concept human trials.
Or we can send an email on your behalf